Table 2.
Summary of JAK inhibitor use in the treatment of dermatologic conditions.
| Study drug | Target | Company | Dermatology indications | ClinicalTrials.gov identifier | Studystatus | References |
|---|---|---|---|---|---|---|
| ORAL JAK INHIBITORS | ||||||
| Tofacitinib | JAK 1/2/3 | Pfizer | AD | NCT02001181 (Ph2) | Completed | (43) |
| Psoriasis |
NCT01710046 (Ph2) NCT01815424 (Ph3) NCT01309737 (Ph3) NCT01276639 (Ph3) NCT01519089 (Ph3) NCT01241591(Ph3) NCT01186744 (Ph3) NCT01163253 (Ph3) |
Completed Completed Completed Completed Completed Completed Completed Completed |
(44) (45) (46) (47) (48) (49) |
|||
| AA, alopecia totalis, alopecia universalis, | NCT02197455 (Ph2) | Completed | (50) | |||
| Dermatomyositis | NCT03002649 (Ph1) | Ongoing | ||||
| Discoid lupus erythematosus, | NCT03159936 (Ph1) | Ongoing | ||||
| cutaneous lupus | NCT03288324 (Ph1/2) | Ongoing | ||||
| Abrocitinib (PF04965842) | JAK1 | Pfizer | Psoriasis | NCT02201524 (Ph2) | Terminated | (51) |
| AD |
NCT02780167 (Ph2) NCT03915496 (Ph2) (JADE MOA) NCT03627767 (Ph2) NCT03349060 (Ph3) (JADE Mono-1) NCT03575871 (Ph3) (JADE Mono-2) NCT03422822 (Ph3) (JADE EXTEND) NCT03720470 (Ph3) (JADE Compare) NCT03796676 (Ph3) (JADE TEEN) |
Completed Ongoing Ongoing Completed Completed Ongoing Ongoing Ongoing |
||||
| PF-06651600 | JAK3 | Pfizer | AA |
NCT02974868 (Ph2) NCT03732807 (Ph2/3) (ALLEGRO-2b/3) |
Completed Ongoing |
|
| Vitiligo | NCT03715829 (Ph2) | Ongoing | ||||
| PF-06700841 | JAK1/ TYK2 | Pfizer | Psoriasis | NCT02969018 (Ph2) | Completed | |
| AA | NCT02974868 (Ph2) | Completed | ||||
| Vitiligo | NCT03715829 (Ph2) | Ongoing | ||||
| PF-06826647 | TYK2 | Pfizer | Psoriasis |
NCT03210961 (Ph1) NCT03895372 (Ph2) |
Completed Ongoing |
|
| Baricitinib | JAK1/2 | Eli Lilly/ Incyte | Psoriasis | NCT01490632 (Ph2) | Completed | (52) |
| AA |
NCT03570749 (Phase 2/3)(BRAVE-AA1) NCT03899259 (Ph3) (BRAVE-AA2) |
Ongoing Ongoing |
||||
| AD |
NCT02576938 (Ph2) NCT03334396 (Ph3) (BREEZE-AD1) NCT03334422 (Ph3) (BREEZE-AD2) NCT03334435 (Ph3) (BREEZE-AD3) NCT03428100 (Ph3) (BREEZE-AD4) NCT03435081 (Ph3) (BREEZE-AD5) NCT03559270 (Ph3) (BREEZE-AD6) NCT03733301 (Ph3) (BREEZE-AD7) NCT03952559 (Ph3) (BREEZE-AD-PEDS) |
Completed Ongoing Completed Ongoing Ongoing Ongoing Ongoing Ongoing Ongoing |
(53) (42) (42) |
|||
| Ruxolitinib | JAK1/2 | Incyte | AA | NCT01950780 (Ph2) | Completed | (54) |
| Itacitinib | JAK1 | Incyte | Psoriasis | NCT01634087 (Ph2) | Completed | (55) |
| INCB054707 | JAK1 | Incyte | Hidradenitis suppurativa |
NCT03569371 (Ph2) NCT03607487 (Ph2) |
Completed Ongoing |
|
| Upadacitinib | JAK1 | AbbVie | AD |
NCT03646604 (Ph1) NCT02925117 (Ph2) NCT03569293 (Ph3) (Measure Up 1) NCT03568318 (Ph3) (AD Up) NCT03738397 (Ph3) (Heads Up) NCT03607422 (Ph3) NCT03661138 (Ph3) |
Ongoing Completed Ongoing Ongoing Ongoing Ongoing Ongoing |
(41) |
| ATI-501 | JAK1/3 | Aclaris | AA, alopecia totalis, alopecia universalis | NCT03594227 (Ph2) | Completed | |
| ORAL JAK INHIBITORS | ||||||
| ASN002 | JAK1/2/3 Tyk2 SYK | Asana BioSciences | AD |
NCT03139981 (Ph1) NCT03654755 (Ph2) NCT03531957 (Ph2) (RADIANT) |
Completed Ongoing Ongoing |
(56) |
| Chronic hand eczema | NCT03728504 (Ph2) | Ongoing | ||||
| Filgotinib | JAK1 | Galapagos NV | Cutaneous lupus | NCT03134222 (Ph2) | Ongoing | |
| GSK2586184 | JAK1 | GSK | Psoriasis | NCT01782664 (Ph2) | Completed | |
| BMS-986165 | TYK2 | BMS | Psoriasis |
NCT03004768 (Ph1) NCT02931838 (Ph2) NCT03924427 (Ph3) NCT03624127 (Ph3) (POETYK-PSO-1) NCT03611751 (Ph3) (POETYK-PSO-2) |
Completed Completed Ongoing Ongoing Ongoing |
(57) |
| Lestaurtinib | JAK2 | Teva/Cephalon | Psoriasis | NCT00236119 (Ph2) | Completed | |
| Peficitinib | JAK3 | Astellas | Psoriasis | NCT01096862 (Ph2) | Completed | (58) |
| CTP-543 | JAK1/2 | Concert Pharma-ceuticals | AA |
NCT03137381 (Ph2) NCT03898479 (Ph2) NCT03941548 (Ph2) NCT03811912 (Ph2) |
Completed Ongoing Ongoing Ongoing |
|
| Study drug | Target | Manufacture | Dermatology indications | ClinicalTrials.gov identifier | ||
| TOPICAL JAK INHIBITORS | ||||||
| Tofacitinib | JAK1/2/3 | Pfizer | Psoriasis |
NCT01831466 (Ph2) NCT01246583 (Ph2) |
Completed Completed |
(59) (60) |
| AD | NCT02001181 (Ph2) | Completed | (43) | |||
| AA | NCT02812342 (Ph2) | Completed | (61) | |||
| PF-06700841 | JAK1/ TYK2 | Pfizer | Psoriasis | NCT03850483 (Ph2) | Ongoing | |
| AD | NCT03903822 (Ph2) | Ongoing | ||||
| Ruxolitinib | JAK1/2 | Incyte | Psoriasis |
NCT00820950 (Ph2) NCT00778700 (Ph2) NCT00617994 (Ph2) |
Completed Completed Completed |
(62) (63) |
| AD |
NCT03257644 (Ph2) NCT03011892 (Ph2) NCT03745638 (Ph3) (TRuE-AD1) NCT03745651 (Ph3) (TRuE AD2) |
Ongoing Completed Ongoing Ongoing |
(64, 65) | |||
| AA | NCT02553330 (Ph2) | Terminated | ||||
| Vitiligo |
NCT03099304 (Ph2) NCT02809976 (Ph2) |
Ongoing Completed |
(66, 67) | |||
| ATI-502 (ATI-50002) | JAK1/3 | Aclaris | AD | NCT03585296 (Ph2) | Completed | |
| AA, alopecia totalis, alopecia universalis |
NCT03315689 (Ph2-AU and AT) NCT03551821 (Ph2-eyebrow) NCT03354637 (Ph2) NCT03759340 (Ph2) |
Completed Completed Ongoing Ongoing |
||||
| Androgenetic alopecia | NCT03495817 (Ph2) | Ongoing | ||||
| Vitiligo | NCT03468855 (Ph2) | Ongoing | ||||
| Delgocitinib (JTE-052) | JAK1/2/3 Tyk Syk | Japan Tobacco Inc.; Leo | AD |
NCT03826901 (Ph1) NCT03725722 (Ph2) (mild to severe AD) |
Ongoing Ongoing |
|
| Chronic hand eczema | NCT03683719 (Ph2) | Ongoing | ||||
| AA |
NCT02561585 (Ph2) NCT03325296 (Ph2-eyebrow) |
Completed Terminated |
||||
| Discoid lupus | NCT03958955 (Ph2) | Ongoing | ||||
AA, alopecia areata; AD, atopic dermatitis; JAK, Janus kinase; TYK, tyrosine kinase.